Interleukin-2, usually called IL-2, is a small signaling protein produced mainly by a specific subset of immune cells, and it acts as a master regulator of the immune response. It was one of the first cytokines ever discovered, and its influence reaches into nearly every corner of immunology, from fighting cancer to preventing the immune system from attacking the body’s own tissues. What makes IL-2 so fascinating, and so tricky to work with medically, is that it simultaneously revs up immune attacks and keeps those attacks in check, depending on which cells receive the signal and how much of it is around.
What IL-2 Actually Does
IL-2 is produced primarily by activated CD4+ T cells, the immune cells sometimes called “helper” cells. When these cells encounter a foreign threat and receive the right activation signals, transcription factors called NFAT and AP-1 switch on the IL-2 gene, and the cell begins pumping out IL-2 protein.1PubMed Central. Novel NFAT sites that mediate activation of the interleukin-2 promoter in response to T-cell receptor stimulation Once released, IL-2 doesn’t just act on the cell that made it. It spreads to neighboring immune cells and tells them to multiply, differentiate, and become more effective.
The list of cell types that respond to IL-2 is long. Killer T cells ramp up their ability to destroy infected or cancerous cells. Helper T cells proliferate and coordinate broader immune responses. Natural killer cells become more cytotoxic. And regulatory T cells, which exist specifically to dampen immune activity, depend on IL-2 for their survival and function. This breadth of action is why IL-2 has been described as a pleiotropic cytokine: it does many things to many cell types, and the outcome depends heavily on context.2PubMed Central. Signaling and Function of Interleukin-2 in T Lymphocytes
How the IL-2 Receptor Assembles
To understand why IL-2 can have such different effects on different cells, you need to know a bit about its receptor. The IL-2 receptor comes in three pieces, called alpha (IL-2Rα, also known as CD25), beta (IL-2Rβ), and gamma (γc, the “common gamma chain” shared by several cytokine receptors). These pieces assemble in a stepwise fashion: IL-2 first grabs onto the alpha chain, then the beta chain joins, and finally the gamma chain completes the complex.3PubMed Central. Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor
The alpha chain acts like a sticky trap that captures IL-2 at very low concentrations. Cells that carry all three subunits on their surface, forming the “high-affinity” receptor, respond to tiny amounts of IL-2. Regulatory T cells are loaded with CD25, which is one reason they are so sensitive to IL-2 signaling. Other immune cells, like resting killer T cells and natural killer cells, usually carry only the beta and gamma chains, forming a lower-affinity receptor. They need much more IL-2 around before they respond. This difference in receptor composition is the key to almost every attempt to use IL-2 therapeutically: the dose determines which cell populations get activated.
Signaling Inside the Cell
Once IL-2 binds its receptor, the intracellular portions of the beta and gamma chains activate enzymes called JAK1 and JAK3. Research in human T cells showed that IL-2 stimulates JAK3 to a significantly greater extent than JAK1, and that robust IL-2-driven cell proliferation can occur through JAK3 activation alone.4PubMed. Activation of JAK3, but not JAK1, is critical for IL-2-induced proliferation and STAT5 recruitment by a COOH-terminal region of the IL-2 receptor beta-chain These JAK enzymes then activate STAT proteins, particularly STAT5 and STAT3, which travel into the nucleus and switch on genes that drive cell survival, growth, and specialization.5PubMed. Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15 Beyond turning on genes, IL-2 also reprograms the cell’s metabolism, shifting it toward the rapid energy production needed for an immune cell that is about to divide and fight.
The Paradox of Immune Activation and Immune Restraint
IL-2’s most striking feature is that it plays for both teams. On one hand, it drives aggressive immune responses. On the other, it is essential for maintaining immune tolerance, the process by which the body prevents its own immune cells from attacking healthy tissue.
The tolerance side works through two distinct mechanisms. First, IL-2 is the critical survival signal for regulatory T cells. These cells suppress overactive immune responses, and without IL-2, they lose both their numbers and their ability to function. Research has shown that even when regulatory T cell survival is rescued through other means, without IL-2 signaling those cells still fail to suppress autoimmune disease. IL-2 directly controls expression of suppressive molecules on regulatory T cells, making them functionally effective.6PubMed Central. Cutting edge: mechanisms of IL-2-dependent maintenance of functional regulatory T cells
Second, IL-2 promotes what immunologists call activation-induced cell death. After T cells have done their job fighting an infection, IL-2 helps trigger a self-destruct program in those cells through the Fas pathway. It does this by increasing the production of Fas ligand on the cell surface while simultaneously suppressing FLIP, a molecule that protects cells from Fas-triggered death.7PubMed. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis This cleanup process prevents armies of activated T cells from hanging around and causing damage once the threat is gone. IL-15, a closely related cytokine, actually opposes this process and helps some T cells survive to become long-lived memory cells.8PubMed Central. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice
Building Immune Memory
IL-2 also plays a surprisingly specific role in how the immune system forms lasting memories of past infections. Studies using timed gene deletion in antigen-specific CD8+ T cells (the killer cells) revealed that IL-2 produced by the cell itself, known as autocrine IL-2, is required during early immune responses to program those cells for strong recall expansion later. In other words, a killer T cell that doesn’t make its own IL-2 during its first encounter with a pathogen will generate weaker responses if it meets that pathogen again. Meanwhile, IL-2 supplied by nearby cells was sufficient for the initial burst of growth and effector function.9Cell Reports. Autocrine IL-2 signaling is required during early primary T cell responses to program secondary expansion potential of memory CD8 T cells This finding matters for vaccine design: it suggests that the quality of IL-2 signaling during vaccination could influence how robust the long-term protection turns out to be.
Natural Killer Cells and the LAK Cell Story
IL-2 isn’t limited to T cells. Natural killer (NK) cells, which are part of the innate immune system and can kill virus-infected or cancerous cells without prior sensitization, respond strongly to IL-2. Exposing NK cells to IL-2 increases their proliferation in a dose- and time-dependent manner.10PubMed Central. Effect of interleukins (IL-2, IL-15, IL-18) on receptors activation and cytotoxic activity of natural killer cells in breast cancer cell
This property led to one of the earliest and most dramatic uses of IL-2 in medicine. In the 1980s, researchers discovered that culturing a patient’s blood cells with IL-2 for a few days generated what they called lymphokine-activated killer (LAK) cells, which could destroy tumor cells that were normally resistant to NK cell killing. LAK activity developed against the vast majority of fresh solid tumor samples tested.11PubMed Central. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes Although LAK cell therapy itself largely gave way to more refined approaches, it demonstrated that IL-2 could unlock immune-mediated cancer killing and paved the way for modern immunotherapy.
High-Dose IL-2 for Cancer
High-dose IL-2 (sold under the name aldesleukin) was approved in the 1990s for metastatic kidney cancer and melanoma. It remains one of the few treatments that has produced complete responses lasting decades in some patients with advanced solid tumors. Many of those complete responders have effectively been cured, needing no further therapy.12PubMed Central. High dose interleukin-2 (Aldesleukin) – expert consensus on best management practices-2014
More recent data have confirmed this durability. In a contemporary cohort, about 5% of metastatic melanoma patients and 6% of metastatic kidney cancer patients achieved complete responses to high-dose IL-2. Median overall survival was roughly 20 months for melanoma patients and 41 months for kidney cancer patients. For those who did achieve a complete or partial response, median overall survival was not reached during follow-up, meaning the majority of responders were still alive years later.13PubMed Central. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma Long-term follow-up has documented progression-free survival stretching from five years to over thirty years in some patients, with dozens of patients alive more than a decade after treatment.14PubMed Central. Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2
The catch is that response rates are low and the treatment is brutal. High-dose IL-2 causes severe toxicity in most patients, which is why it has always been restricted to specialized centers and carefully selected patients.
Why High-Dose IL-2 Is So Toxic
The signature side effect of high-dose IL-2 therapy is capillary leak syndrome, a condition in which fluid leaks out of blood vessels into surrounding tissues, causing dangerous drops in blood pressure, organ swelling, and sometimes multi-organ dysfunction. Early research suggested that intravenous IL-2 leads to widespread activation of the cells lining blood vessels (endothelial cells), likely through the production of secondary inflammatory cytokines such as tumor necrosis factor and interferon-gamma.15The Journal of Immunology. Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome
More recent work has added complexity to this picture. A 2025 study using human endothelial cells co-cultured with immune cells found that neither IL-2 alone nor the cocktail of cytokines released by IL-2-stimulated immune cells was sufficient to break down the vascular barrier on its own. Direct physical contact between activated immune cells and endothelial cells was required for the barrier to fail.16PubMed Central. An immune competent in vitro model of IL2 induced vascular leakage enables mechanistic insights and evaluation of mitigation strategies This finding suggests the vascular leak is more than just a cytokine storm; it involves immune cells physically interacting with blood vessel walls. Identifying the specific molecules driving that interaction could eventually lead to ways to block the toxicity without losing the anti-tumor benefit.
Low-Dose IL-2 for Autoimmune Disease
The flip side of high-dose IL-2’s immune-boosting toxicity is low-dose IL-2’s ability to selectively expand regulatory T cells. Because regulatory T cells carry the high-affinity receptor (with abundant CD25), they respond to much lower concentrations of IL-2 than effector cells do. This has opened the door to an entirely different therapeutic strategy: giving small amounts of IL-2 to patients with autoimmune diseases in order to strengthen their immune restraint.
Systemic lupus erythematosus has been a leading test case. Lupus patients have defective regulatory T cells partly because their CD4+ T cells underproduced IL-2 and lost CD25 expression. Low-dose IL-2 selectively corrected this defect, both in laboratory experiments and in patients, expanding the regulatory T cell population substantially.17Annals of the Rheumatic Diseases. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus A randomized, placebo-controlled trial confirmed that low-dose IL-2 induced significant expansion of regulatory T cells in lupus patients while leaving overall CD4+ and CD8+ T cell counts unchanged.18Annals of the Rheumatic Diseases. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial Trials in other autoimmune conditions, including type 1 diabetes and graft-versus-host disease, have explored similar strategies.
Engineered IL-2 Variants and Synthetic Mimics
The fact that the same molecule can either boost or suppress immunity depending on the dose has pushed researchers to engineer modified versions of IL-2 that tip the balance one way or the other by design.
One approach produced what researchers call an IL-2 “superkine,” an engineered variant with increased binding affinity for the IL-2Rβ chain. Because this superkine no longer needs CD25 to bind effectively, it activates killer T cells and NK cells more strongly while expanding regulatory T cells proportionally less. In animal studies, it led to improved anti-tumor responses and reduced the lung fluid buildup that typically accompanies IL-2 treatment.19PubMed Central. Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’ Subsequent computational design efforts have replicated these properties, creating additional IL-2 analogs with CD25-independent activity on T and NK cells.20PubMed Central. Interleukin-2 superkines by computational design
A more radical approach has involved designing proteins from scratch. Researchers used computational methods to create entirely new proteins that bind to the IL-2Rβγc receptor complex but share no structural resemblance to natural IL-2 and have no binding site for CD25 or the related IL-15Rα at all.21PubMed Central. De novo design of potent and selective mimics of IL-2 and IL-15 These synthetic mimics represent a new frontier: molecules that deliver the desired immune signals through a completely artificial scaffold, potentially allowing fine-tuned control over which immune cells respond and how strongly.
Combining IL-2 with Checkpoint Inhibitors
Checkpoint inhibitors, the drugs that block PD-1 or CTLA-4 to unleash T cell attacks on tumors, have transformed cancer treatment. But many patients don’t respond or develop resistance. Adding IL-2 to the mix is one strategy being explored to overcome that resistance.
When researchers treated human tumor samples that were resistant to combined CTLA-4 and PD-1 blockade with the addition of IL-2, the triple combination induced T cell activation and deep immunological responses. In a mouse breast cancer model, the triple combination cured nearly twice as many animals as dual checkpoint blockade alone, driven by expansion of tumor-specific killer T cells.22PubMed. Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors Other engineered approaches include fusion proteins that tether IL-2 to a PD-1-targeting antibody, delivering the cytokine signal directly to exhausted T cells at the tumor site and enhancing anti-tumor responses in combination with other immunotherapies.23PubMed Central. A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2Rα strengthens T cell-mediated anti-tumor therapies Additional studies have combined engineered IL-2 variants with radiation therapy and PD-1 blockade, reporting reduced tumor volumes and prolonged survival in preclinical models.24PubMed Central. Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy
IL-2 Disruption in HIV
HIV doesn’t just destroy CD4+ T cells; it also disrupts the IL-2 system those cells depend on. In HIV-infected patients, the IL-2/IL-2 receptor system is dysregulated, with underproduction of IL-2 and defective receptor signaling that may contribute to the progressive collapse of immune function during chronic infection.25PubMed. Interleukin-2: from T cell growth and homeostasis to immune reconstitution of HIV patients Studies examining HIV-specific CD4+ T cells during active viral replication found a reduced percentage of cells producing IL-2, and these cells became dependent on externally supplied IL-2 to proliferate at all.26PubMed Central. Changes in paracrine interleukin-2 requirement, CCR7 expression, frequency, and cytokine secretion of human immunodeficiency virus-specific CD4+ T cells are a consequence of antigen load Separate research confirmed that during viremia, diminished IL-2 production by HIV-specific CD4+ T cells was closely linked to their inability to proliferate in response to the virus.27PubMed Central. Diminished proliferation of human immunodeficiency virus-specific CD4+ T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2
This created hope that giving IL-2 to HIV patients could help rebuild their immune systems. Clinical trials did show that IL-2 could boost CD4+ T cell counts, but large studies ultimately found that the increase in cell numbers didn’t translate into fewer infections or better clinical outcomes, a disappointing result that underscored how much more there is to immune competence than raw cell counts.
Soluble IL-2 Receptor as a Diagnostic Tool
When T cells are activated and CD25 is expressed on their surface, some of it gets shed into the bloodstream as a soluble form called sIL-2R. Measuring sIL-2R in the blood has become a useful diagnostic tool, particularly in sarcoidosis, an inflammatory disease that can affect the lungs and other organs. In sarcoidosis, sIL-2R levels can distinguish patients from healthy individuals, differentiate active from inactive disease, and track how well treatment is working.28PubMed Central. Biological role of the soluble interleukin-2 receptor in sarcoidosis In a study of patients suspected of having sarcoidosis, sIL-2R had a sensitivity of 88% and specificity of 85%, substantially outperforming the traditional blood test (ACE levels), which managed only 62% sensitivity and 76% specificity.29PLoS ONE. Sensitivity and specificity of serum soluble interleukin-2 receptor for diagnosing sarcoidosis in a population of patients suspected of sarcoidosis Elevated sIL-2R also shows up in lymphomas, certain infections, and other conditions where T cells are chronically activated, giving clinicians a broad but informative marker of immune activation.
When the IL-2 Receptor Is Broken From Birth
The common gamma chain (γc), shared by the receptors for IL-2 and several other cytokines including IL-4, IL-7, IL-9, and IL-15, is encoded by a gene on the X chromosome called IL2RG. Mutations in this gene cause X-linked severe combined immunodeficiency, the most common form of SCID, sometimes called “bubble boy disease.”30PubMed. Mutation analysis of IL2RG in human X-linked severe combined immunodeficiency31PubMed. Mutations in the gene for the common gamma chain (gammac) in X-linked severe combined immunodeficiency Children born with these mutations lack functional T cells and NK cells, leaving them defenseless against infections. The condition is fatal without treatment, typically through bone marrow transplant or, increasingly, gene therapy. The severity of X-linked SCID illustrates just how essential the gamma chain signaling hub is for immune development. Without it, not only IL-2 but the entire family of cytokines that share this receptor subunit fails to signal properly.
IL-2 Beyond the Immune System
IL-2 and its receptors are expressed in the brain, and the cytokine appears to be more than just a bystander in the central nervous system. Research has shown that IL-2 promotes survival and neurite extension of cultured neurons, stimulates the proliferation and maturation of oligodendrocytes (the cells that insulate nerve fibers), and can affect hypothalamic-pituitary function and even alter behavior and brain electrical activity.32Biological Signals and Receptors. Interleukin-2 and Its Effects in the Central Nervous System IL-2 and its receptor show region-specific and disease-stage-specific patterns in conditions such as multiple sclerosis, Alzheimer’s disease, and ischemic stroke, appearing at varying levels in plasma, cerebrospinal fluid, and brain tissue depending on the disease and how far it has progressed.33PubMed. Interleukin-2 and its receptors: Implications and therapeutic prospects in immune-mediated disorders of central nervous system Whether IL-2 could be harnessed therapeutically for neurological conditions remains an open question, but the fact that it is active in the brain at all complicates any attempt to give it systemically for immune purposes.
An Ancient Molecule Still Evolving
IL-2’s importance is reflected in its deep evolutionary roots. In mammals, IL-2 and IL-15 share a common ancestor and perform overlapping but distinct functions, using separate “private” receptor chains (IL-2Rα and IL-15Rα respectively) to achieve specificity. Fish, however, appear to have only a single IL-15Rα-like receptor gene and lack a separate IL-2Rα gene. Structural analysis of IL-2 from grass carp revealed a protein that maintains the classic four-helix-bundle shape of mammalian cytokines but more closely resembles human IL-15, with the key receptor-binding amino acids well conserved.34Developmental & Comparative Immunology. Structural insights into the co-evolution of IL-2 and its private receptor in fish The implication is that IL-2 and IL-15 likely diverged from a shared precursor somewhere between fish and mammals, with IL-2 acquiring its own dedicated receptor chain along the way. That evolutionary separation gave the mammalian immune system a new layer of fine-tuning: the ability to independently control the signals that drive immune attack versus those that sustain immune memory, a division of labor that fish manage with a single receptor.